147 related articles for article (PubMed ID: 38305004)
21. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract][Full Text] [Related]
22. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Pegram MD; Bondarenko I; Zorzetto MMC; Hingmire S; Iwase H; Krivorotko PV; Lee KS; Li RK; Pikiel J; Aggarwal R; Ewesuedo R; Freyman A; Li R; Vana A; Yin D; Zacharchuk C; Tan-Chiu E
Br J Cancer; 2019 Jan; 120(2):172-182. PubMed ID: 30568294
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.
Nodehi RS; Kalantari B; Raafat J; Ansarinejad N; Moazed V; Mortazavizadeh SMR; Hosseinzadeh M; Ghaderi B; Jenabian A; Qadyani M; Haghighat S; Allahyari A; Mirzania M; Seghatoleslami M; Payandeh M; Alikhasi A; Kafi H; Shahi F
BMC Pharmacol Toxicol; 2022 Jul; 23(1):57. PubMed ID: 35902898
[TBL] [Abstract][Full Text] [Related]
24. Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US.
Jin R; Mahtani RL; Accortt N; Lawrence T; Sandschafer D; Loaiza-Bonilla A
Ther Adv Med Oncol; 2021; 13():17588359211041961. PubMed ID: 35003333
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India.
Joel A; Georgy JT; Thumaty DB; John AO; Chacko RT; Rebekah G; Sigamani E; Chandramohan J; Manipadam MT; Cherian AJ; Abraham DT; Jacob PM; Sebastian P; Backianathan S; Singh A
Ecancermedicalscience; 2021; 15():1207. PubMed ID: 33912232
[TBL] [Abstract][Full Text] [Related]
26. A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab.
Yang C; Khwaja R; Tang P; Nixon N; King K; Lupichuk S
Curr Oncol; 2022 Jun; 29(6):4224-4234. PubMed ID: 35735446
[TBL] [Abstract][Full Text] [Related]
27. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
28. Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management.
Cuellar S
Am J Manag Care; 2020 Mar; 26(2 Suppl):S32-S40. PubMed ID: 32282173
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
[TBL] [Abstract][Full Text] [Related]
31. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
[TBL] [Abstract][Full Text] [Related]
32. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
[TBL] [Abstract][Full Text] [Related]
33. [Trastuzumab and its biosimilars].
Sarosiek T; Morawski P
Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.
Trojan A; Roth S; Atassi Z; Kiessling M; Zenhaeusern R; Kadvany Y; Schumacher J; Kullak-Ublick GA; Aapro M; Eniu A
JMIR Cancer; 2024 Apr; 10():e54178. PubMed ID: 38573759
[TBL] [Abstract][Full Text] [Related]
36. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of action of the trastuzumab biosimilar CT-P6.
Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
[No Abstract] [Full Text] [Related]
38. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.
Bernat-Peguera A; Trigueros M; Ferrando-Díez A; Ibáñez C; Bystrup S; Martínez-Cardús A; Margelí M; Martínez-Balibrea E
Breast; 2022 Apr; 62():1-9. PubMed ID: 35078146
[TBL] [Abstract][Full Text] [Related]
40. Clinical development of CT-P6 in HER2 positive breast cancer.
Fu C; Stebbing J; Esteva FJ
Expert Opin Biol Ther; 2019 Oct; 19(10):987-992. PubMed ID: 31507219
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]